SG Americas Securities
ACRS icon

SG Americas Securities’s Aclaris Therapeutics ACRS Stock Holding History

SG Americas Securities’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$100K Buy
26,767
+11,344
+74% +$38.3K ﹤0.01% 2938
2025
Q4 		$46K Sell
15,423
-6,589
-30% -$16.6K ﹤0.01% 3367
2025
Q3 		$42K Sell
22,012
-31,347
-59% -$54.6K ﹤0.01% 3216
2025
Q2 		$76K Sell
53,359
-14,574
-21% -$19.7K ﹤0.01% 2689
2025
Q1 		$104K Buy
+67,933
New +$145K ﹤0.01% 3015
2024
Q2 		– Sell
-32,843
Closed -$41K – 2808
2024
Q1 		$41K Buy
32,843
+13,461
+69% +$16.1K ﹤0.01% 2795
2023
Q4 		$20K Sell
19,382
-132,322
-87% -$404K ﹤0.01% 3002
2023
Q3 		$1.04M Buy
151,704
+25,357
+20% +$217K 0.01% 1233
2023
Q2 		$1.31M Buy
126,347
+96,504
+323% +$873K 0.01% 938
2023
Q1 		$241K Buy
29,843
+22,482
+305% +$285K ﹤0.01% 2291
2022
Q4 		$116K Sell
7,361
-6,237
-46% -$100K ﹤0.01% 2623
2022
Q3 		$214K Buy
+13,598
New +$214K ﹤0.01% 2271
2022
Q1 		– Sell
-13,679
Closed -$199K – 2917
2021
Q4 		$199K Sell
13,679
-7,333
-35% -$111K ﹤0.01% 2665
2021
Q3 		$378K Buy
+21,012
New +$337K ﹤0.01% 2745
2020
Q2 		– Sell
-13,280
Closed -$14K – 3661
2020
Q1 		$14K Buy
+13,280
New +$18.1K ﹤0.01% 3332
2017
Q2 		– Sell
-13,968
Closed -$417K – 3146
2017
Q1 		$417K Buy
+13,968
New +$403K ﹤0.01% 1965

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

SG Americas Securities's ACRS Position: Q1 2026 in Review

SG Americas Securities increased its Aclaris Therapeutics (ACRS) stake by 74% in Q1 2026, buying an estimated $38.3K and bringing the position to 26,767 shares worth $100K. The position accounts for ﹤0.01% of the portfolio, ranked #2938.

SG Americas Securities first reported a position in ACRS in Q1 2017 and has held it in 16 quarters since. The position peaked at $1.31M in Q2 2023. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • SG Americas Securities held 26,767 shares of Aclaris Therapeutics worth $100K as of Q1 2026.
  • SG Americas Securities bought 11,344 Aclaris Therapeutics shares in Q1 2026, an estimated $38.3K.
  • Aclaris Therapeutics made up ﹤0.01% of SG Americas Securities's portfolio in Q1 2026, its #2938 holding.
  • SG Americas Securities first reported a position in Aclaris Therapeutics in Q1 2017 and has held it in 16 quarters since.
  • SG Americas Securities's Aclaris Therapeutics position peaked at $1.31M in Q2 2023.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on SG Americas Securities's 13F filing for Q1 2026, filed 16 Apr 2026.